UNSPSC 51381515: Tolmetin sodium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H14NO3.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02N1TZF99F, chemically known as 1h-pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)- but more generally known as tolmetin sodium, which bears US NIH Compound Identifier 5509. European Medicines Agency schedules Tolmetin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04908MIG.

Most nations, for tariff and trade purposes, schedule tolmetin sodium under HS 29339990 and SITC 51577. As of Q4 2014, TOLMETIN SODIUM remains US FDA's Preferred Term for this commodity. Tolmetin sodium bears US NLM identifiers UMLS ID C0087097 and NCI Concept Code C61977. SMILES: CC1CCC(CC1)C(=O)C2CCC(N2C)CC(=O)[O-].O.O.[NA+].

UNSPSC 51381515 Tolmetin sodium is a Commodity code with minimal recent alignment between its nominal scope and actual state and local procurement activity. The recent opportunities tagged under this code show no purchases of tolmetin sodium itself; instead, they reflect procurement of naloxone and drug deactivation systems, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals and OTC products—categories that fall well outside the analgesic nonsteroidal anti-inflammatory drug family the code nominally covers. State and local issuers accessing pharmaceutical supply include state health departments, county health systems, and cooperative purchasing alliances serving multi-state networks of government entities. The issuing bodies in recent records include Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration.

Activity spans Florida, Texas, and the Upper Midwest, with cooperative purchasing extending across state lines. Recent solicitations include Seminole County's IFB 60459723LAS, an invitation for bid posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, exploring direct-to-manufacturer prescription programs without formal evaluation criteria or award timelines; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with a proposal deadline of March 26, 2026, requiring vendors to meet cGMP and DSCSA compliance and maintain relationships with specified wholesalers. The code shows little relevant recent activity for tolmetin sodium specifically and appears to be a tagging artifact rather than an active procurement category for the products and services state and local governments are currently buying.